SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burde	en									
hours per response:	0.5									

1. Name and Addres <u>WIGGINS M</u>	s of Reporting Person	n*	2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC [BIIB]		ionship of Reporting Perso all applicable) Director	n(s) to Issuer 10% Owner
(Last) (Eirst) (Middle) I		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/16/2007	X	Officer (give title below) EVP Corp. and Bu	Other (specify below) s. Dev.
(Street) CAMBRIDGE	МА	02142	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	dual or Joint/Group Filing (Form filed by One Report Form filed by More than 0 Person	ting Person
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or Price Transact		Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	04/16/2007		M ⁽¹⁾		5,000	A	\$35.37	27,967.68 ⁽²⁾	D		
Common Stock	04/16/2007		S ⁽¹⁾		5,000	D	\$45.57	22,967.68	D		
Common Stock								676.773	Ι	Trust	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4			
Stock Option (Right-to- buy) ⁽³⁾	\$35.37	04/16/2007		M ⁽¹⁾			5,000	(4)	01/21/2013	Common Stock	5,000	(5)	40,697	D	

Explanation of Responses:

1. Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

2. Includes 733.57 shares acquired under the Biogen Idec Inc. Employee Stock Purchase Plan on 3/30/2007.

3. Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).

4. The stock options became exercisable in five (5) installments on 12/31/2003, 12/1/2004, 12/1/2005, 11/1/2006, and 12/1/2006.

5. Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).

Remarks:

By: Robert Licht attorney-infact for Mark C. Wiggins

04/17/2007

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.